+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
All Genders
ID06666270

Phase I Study of Oral SYN818 for Advanced or Metastatic Solid Tumors Including Breast, Ovarian, and Prostate Cancer

Led by Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd · Updated on 2025-07-20

30

Participants Needed

2

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating SYN818, a DNA Polymerase Theta POLQ inhibitor, as a treatment for adults with locally advanced or metastatic solid tumors, including breast, ovarian, and prostate cancers. This Phase I, open-label, multicenter study aims to assess the safety, tolerability, how the body processes the drug, its effects on the body, and preliminary anti-tumor activity. The study is sponsored by Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd and focuses on patients who have progressed despite standard therapies. Participants will receive SYN818 orally as a tablet monotherapy. The treatment is given in cycles lasting 21 days, with ongoing monitoring to identify the maximum tolerated dose and any dose-limiting toxicities. The study involves up to three years of follow-up to assess safety, pharmacokinetics, pharmacodynamics, and tumor response. Patients must provide tumor tissue or blood samples for genetic testing related to BRCA mutation or homologous recombination repair deficiency. During the study, participants will undergo regular evaluations including scans for measurable lesions, blood tests to monitor tumor markers like CA125 and PSA, and monitoring for adverse events. Researchers will track how long responses last, time to response, and progression-free survival. Safety is monitored from consent through 30 days post-treatment, with toxicity assessments during the first treatment cycle. The total follow-up can last up to three years to observe long-term effects and outcomes.

CONDITIONS

Brief Title

Study of SYN818 for the Treatment of Advanced or Metastatic Solid Tumors

Research Team

T

Tongfu Xu, PHD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here